The FDA on August 19, 2021 approved OPDIVO® for the adjuvant treatment of patients with Urothelial Carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. OPDIVO® is a product of Bristol-Myers Squibb Co.
Bottom Ad
Advertisement
Subscribe
